共役モノクローナル抗体の世界市場レポート 2025年

共役モノクローナル抗体市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.3％で146億4,000万米ドルに成長します。予測期間の成長は、ヘルスケアへのアクセス向上、低侵襲手技の需要拡大、免疫療法との併用、医療アクセスの拡大、適応症の拡大などに起因すると考えられます。予測期間における主な動向としては、ドラッグデリバリーの進歩、バイオマーカー主導の開発、次世代コンジュゲート、患者中心の医療などが挙げられます。

共役モノクローナル抗体、特に抗体薬物複合体（ADC）の人気の高まりと治療の可能性は、市場の需要を促進すると予測されます。ADCはモノクローナル抗体と強力な細胞傷害性薬剤をリンカーで結合させたもので、抗原を発現する腫瘍細胞を標的とし、主にがん治療に用いられています。米国食品医薬品局が過去数年間に承認したADCはわずか3種類であったにもかかわらず、承認数の増加と、特にがん治療における共役モノクローナル抗体の応用との相関関係が、市場の成長軌道を実証しています。

がんの著しい蔓延は、共役モノクローナル抗体市場の今後の成長を促進すると予想されます。がんは、体内の異常細胞の制御不能な増殖と拡散を特徴とするさまざまな疾患を包含し、腫瘍や腫瘤の形成につながる可能性があります。共役モノクローナル抗体は、標的を絞った正確な作用により、主にがん治療に利用され、患者の全体的な生活の質を向上させる。例えば、2024年9月に米国がん協会が発表した報告書によると、2050年までに世界の男性のがん患者数は84％急増し、2022年の1,030万人から1,900万人に増加すると予測され、がん関連死は93％増加し、2022年の540万人から1,050万人に増加すると予測されています。その結果、がんの罹患率の高さが共役モノクローナル抗体市場の成長に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界共役モノクローナル抗体PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の共役モノクローナル抗体市場：成長率分析
• 世界の共役モノクローナル抗体市場の実績：規模と成長, 2019-2024
• 世界の共役モノクローナル抗体市場の予測：規模と成長, 2024-2029, 2034F
• 世界共役モノクローナル抗体総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の共役モノクローナル抗体市場薬物によって、実績と予測, 2019-2024, 2024-2029F, 2034F
• アドセトリス
• カドシラ
• 世界の共役モノクローナル抗体市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 切断可能なリンカー
• 切断不可能なリンカー
• 世界の共役モノクローナル抗体市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液がん
• 乳がん
• 卵巣がん
• 肺がん
• 脳腫瘍
• その他の用途
• 世界の共役モノクローナル抗体市場、Adcetrisのサブセグメント、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ブレンツキシマブ・ベドチン
• 世界の共役モノクローナル抗体市場、カドシラのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• トラスツズマブエムタンシン

第7章 地域別・国別分析

• 世界の共役モノクローナル抗体市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の共役モノクローナル抗体市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 共役モノクローナル抗体市場：競合情勢
• 共役モノクローナル抗体市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Immunomedics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceuticals Industries Ltd.
• Daiichi Sankyo Company Limited
• Actinium Pharmaceuticals
• Nordic Nanovector Inc.
• Spectrum Pharmaceuticals Inc.
• AbbVie Inc.
• Bayer AG
• AstraZeneca plc
• Novartis AG
• Amgen
• Celgene
• Genentech
• Emergent BioSolutions
• Genzyme
• Incyte Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 共役モノクローナル抗体市場2029：新たな機会を提供する国
• 共役モノクローナル抗体市場2029：新たな機会を提供するセグメント
• 共役モノクローナル抗体市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Conjugated monoclonal antibodies refer to compounds resulting from chemically binding a medication to a monoclonal antibody. These antibodies specifically target proteins or receptors on particular cell types, such as cancer cells, allowing the associated medication to enter these cells, eliminate them, and spare healthy cells.

The primary drugs categorized as conjugated monoclonal antibodies are Adcetris and Kadcyla. Adcetris, a brand-name medication, is designed to treat specific forms of lymphoma in adults. Lymphoma is a type of cancer affecting the lymphatic system and lymphocytes, a type of white blood cell. These therapies utilize various technologies, including cleavable and non-cleavable linkers, and find application in treating conditions such as blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumors, and other malignancies.

The conjugated monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides conjugated monoclonal antibodies market statistics, including industry global market size, regional shares, competitors with a conjugated monoclonal antibodies market share, detailed conjugated monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the conjugated monoclonal antibodies industry. The conjugated monoclonal antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The conjugated monoclonal antibodies market size has grown strongly in recent years. It will grow from $10.9 billion in 2024 to $11.48 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to the increasing prevalence of cancer, expansion of the private healthcare sector, government support, and growing patient population.

The conjugated monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $14.64 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increased access to healthcare, growing demand for minimally invasive procedures, immunotherapeutic combinations, expanding healthcare access, and expanding indications. Major trends in the forecast period include advances in drug delivery, biomarker-driven development, next-generation conjugates, and patient-centric care.

The rising popularity and therapeutic potential of conjugated monoclonal antibodies, specifically antibody-drug conjugates (ADCs), are projected to fuel demand within the market. ADCs, comprising monoclonal antibodies coupled with potent cytotoxic drugs through linkers to target antigen-expressing tumor cells, are primarily employed in cancer treatment. Despite the U.S. Food and Drug Administration approving only three ADCs in the past few years, the correlation between increased approvals and the application of conjugated monoclonal antibodies, particularly in cancer treatment, substantiates the market's growth trajectory.

The significant prevalence of cancer is anticipated to drive the growth of the conjugated monoclonal antibodies market in the future. Cancer encompasses a range of diseases characterized by the uncontrolled proliferation and dissemination of abnormal cells within the body, which can lead to the formation of tumors or masses. Conjugated monoclonal antibodies are mainly utilized in cancer treatment due to their targeted and precise action, which enhances the overall quality of life for patients. For example, a report from the American Cancer Society in September 2024 indicated that by 2050, the number of cancer cases in men worldwide is expected to surge by 84%, rising from 10.3 million in 2022 to 19 million, while cancer-related deaths are projected to increase by 93%, from 5.4 million in 2022 to 10.5 million. Consequently, the high incidence of cancer is fueling the growth of the conjugated monoclonal antibodies market.

Leading firms operating in the realm of conjugated monoclonal antibodies are leveraging strategic partnerships to bolster their capabilities and offer comprehensive solutions. These partnerships entail companies leveraging each other's strengths and resources for mutual success. For example, in July 2023, BeiGene Ltd., a U.S.-based biotech firm, joined forces with Duality Biologics, a China-based clinical stage company, aiming to develop and commercialize a preclinical antibody-drug conjugate (ADC) therapy targeting specific solid tumors. The combined strengths of both entities are poised to expedite the development and market entry of this promising ADC therapy.

In June 2023 was indeed aimed at bolstering Lonza's capabilities in the development and manufacturing of antibody-drug conjugates (ADCs). The acquisition was focused on enhancing Lonza's ADC portfolio and gaining access to Synaffix's pipeline of ADC candidates. The specific financial details of the acquisition were not disclosed.

Major companies operating in the conjugated monoclonal antibodies market include Pfizer Inc., F. Hoffmann-La Roche AG, Bristol -Myers Squibb, Merck & Co. Inc., Immunomedics Inc., Takeda Pharmaceuticals Industries Ltd., Daiichi Sankyo Company Limited, Actinium Pharmaceutical, Nordic Nanovector Inc., Spectrum Pharmaceuticals Inc., AbbVie Inc., Bayer AG, AstraZeneca plc, Novartis AG, Amgen, Celgene, Emergent BioSolutions, Genzyme, Incyte Corporation, Kite Pharma, MorphoSys AG, Regeneron Pharmaceuticals, Seattle Genetics

North America was the largest region in the conjugated monoclonal antibody market in 2024. The Middle East is expected to be the fastest growing region in the global conjugated monoclonal antibodies market share during the forecast period. The regions covered in the conjugated monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the conjugated monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The conjugated monoclonal antibodies market consists of sales of Brentuximab vedotin and Ado-trastuzumab emtansine. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Conjugated Monoclonal Antibodies Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on conjugated monoclonal antibodies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for conjugated monoclonal antibodies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The conjugated monoclonal antibodies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Adcetris; Kadcyla
• 2) By Technology: Cleavable Linker; Non-cleavable Linker
• 3) By Application: Blood Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
• Subsegments:
• 1) By Adcetris: Brentuximab Vedotin
• 2) By Kadcyla: Trastuzumab Emtansine
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Bristol -Myers Squibb; Merck & Co. Inc.; Immunomedics Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Conjugated Monoclonal Antibodies Market Characteristics

3. Conjugated Monoclonal Antibodies Market Trends And Strategies

4. Conjugated Monoclonal Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Conjugated Monoclonal Antibodies Growth Analysis And Strategic Analysis Framework

• 5.1. Global Conjugated Monoclonal Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Conjugated Monoclonal Antibodies Market Growth Rate Analysis
• 5.4. Global Conjugated Monoclonal Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Conjugated Monoclonal Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Conjugated Monoclonal Antibodies Total Addressable Market (TAM)

6. Conjugated Monoclonal Antibodies Market Segmentation

• 6.1. Global Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adcetris
• Kadcyla
• 6.2. Global Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cleavable Linker
• Non-cleavable Linker
• 6.3. Global Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Cancer
• Breast Cancer
• Ovarian Cancer
• Lung Cancer
• Brain Tumor
• Other Applications
• 6.4. Global Conjugated Monoclonal Antibodies Market, Sub-Segmentation Of Adcetris, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Brentuximab Vedotin
• 6.5. Global Conjugated Monoclonal Antibodies Market, Sub-Segmentation Of Kadcyla, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Trastuzumab Emtansine

7. Conjugated Monoclonal Antibodies Market Regional And Country Analysis

• 7.1. Global Conjugated Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Conjugated Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Conjugated Monoclonal Antibodies Market

• 8.1. Asia-Pacific Conjugated Monoclonal Antibodies Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Conjugated Monoclonal Antibodies Market

• 9.1. China Conjugated Monoclonal Antibodies Market Overview
• 9.2. China Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Conjugated Monoclonal Antibodies Market

• 10.1. India Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Conjugated Monoclonal Antibodies Market

• 11.1. Japan Conjugated Monoclonal Antibodies Market Overview
• 11.2. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Conjugated Monoclonal Antibodies Market

• 12.1. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Conjugated Monoclonal Antibodies Market

• 13.1. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Conjugated Monoclonal Antibodies Market

• 14.1. South Korea Conjugated Monoclonal Antibodies Market Overview
• 14.2. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Conjugated Monoclonal Antibodies Market

• 15.1. Western Europe Conjugated Monoclonal Antibodies Market Overview
• 15.2. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Conjugated Monoclonal Antibodies Market

• 16.1. UK Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Conjugated Monoclonal Antibodies Market

• 17.1. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Conjugated Monoclonal Antibodies Market

• 18.1. France Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Conjugated Monoclonal Antibodies Market

• 19.1. Italy Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Conjugated Monoclonal Antibodies Market

• 20.1. Spain Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Conjugated Monoclonal Antibodies Market

• 21.1. Eastern Europe Conjugated Monoclonal Antibodies Market Overview
• 21.2. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Conjugated Monoclonal Antibodies Market

• 22.1. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Conjugated Monoclonal Antibodies Market

• 23.1. North America Conjugated Monoclonal Antibodies Market Overview
• 23.2. North America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Conjugated Monoclonal Antibodies Market

• 24.1. USA Conjugated Monoclonal Antibodies Market Overview
• 24.2. USA Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Conjugated Monoclonal Antibodies Market

• 25.1. Canada Conjugated Monoclonal Antibodies Market Overview
• 25.2. Canada Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Conjugated Monoclonal Antibodies Market

• 26.1. South America Conjugated Monoclonal Antibodies Market Overview
• 26.2. South America Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Conjugated Monoclonal Antibodies Market

• 27.1. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Conjugated Monoclonal Antibodies Market

• 28.1. Middle East Conjugated Monoclonal Antibodies Market Overview
• 28.2. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Conjugated Monoclonal Antibodies Market

• 29.1. Africa Conjugated Monoclonal Antibodies Market Overview
• 29.2. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Conjugated Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Conjugated Monoclonal Antibodies Market Competitive Landscape And Company Profiles

• 30.1. Conjugated Monoclonal Antibodies Market Competitive Landscape
• 30.2. Conjugated Monoclonal Antibodies Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Immunomedics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Conjugated Monoclonal Antibodies Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceuticals Industries Ltd.
• 31.2. Daiichi Sankyo Company Limited
• 31.3. Actinium Pharmaceuticals
• 31.4. Nordic Nanovector Inc.
• 31.5. Spectrum Pharmaceuticals Inc.
• 31.6. AbbVie Inc.
• 31.7. Bayer AG
• 31.8. AstraZeneca plc
• 31.9. Novartis AG
• 31.10. Amgen
• 31.11. Celgene
• 31.12. Genentech
• 31.13. Emergent BioSolutions
• 31.14. Genzyme
• 31.15. Incyte Corporation

32. Global Conjugated Monoclonal Antibodies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Conjugated Monoclonal Antibodies Market

34. Recent Developments In The Conjugated Monoclonal Antibodies Market

35. Conjugated Monoclonal Antibodies Market High Potential Countries, Segments and Strategies

• 35.1 Conjugated Monoclonal Antibodies Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Conjugated Monoclonal Antibodies Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Conjugated Monoclonal Antibodies Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer